150 related articles for article (PubMed ID: 11747625)
1. Mapping of IFN-beta epitopes important for receptor binding and biologic activation: comparison of results achieved using antibody-based methods and alanine substitution mutagenesis.
Runkel L; De Dios C; Karpusas M; Baker D; Li Z; Zafari M; Betzenhauser M; Muldowney C; Miller S; Redlich PN; Grossberg SE; Whitty A; Hochman PS
J Interferon Cytokine Res; 2001 Nov; 21(11):931-41. PubMed ID: 11747625
[TBL] [Abstract][Full Text] [Related]
2. Identification of critical residues in bovine IFNAR-1 responsible for interferon binding.
Cutrone EC; Langer JA
J Biol Chem; 2001 May; 276(20):17140-8. PubMed ID: 11278538
[TBL] [Abstract][Full Text] [Related]
3. Systematic mutational mapping of sites on human interferon-beta-1a that are important for receptor binding and functional activity.
Runkel L; deDios C; Karpusas M; Betzenhauser M; Muldowney C; Zafari M; Benjamin CD; Miller S; Hochman PS; Whitty A
Biochemistry; 2000 Mar; 39(10):2538-51. PubMed ID: 10704203
[TBL] [Abstract][Full Text] [Related]
4. Identification of a linear epitope of interferon-alpha2b recognized by neutralizing monoclonal antibodies.
Blank VC; Sterin-Prync A; Retegui L; Vidal A; Criscuolo M; Roguin LP
Eur J Biochem; 1999 Oct; 265(1):11-9. PubMed ID: 10491153
[TBL] [Abstract][Full Text] [Related]
5. Structure-function study of the extracellular domain of the human IFN-alpha receptor (hIFNAR1) using blocking monoclonal antibodies: the role of domains 1 and 2.
Lu J; Chuntharapai A; Beck J; Bass S; Ow A; De Vos AM; Gibbs V; Kim KJ
J Immunol; 1998 Feb; 160(4):1782-8. PubMed ID: 9469437
[TBL] [Abstract][Full Text] [Related]
6. Epitope Mapping of Neutralizing Monoclonal Antibodies to Human Interferon-γ Using Human-Bovine Interferon-γ Chimeras.
Zuber B; Rudström K; Ehrnfelt C; Ahlborg N
J Interferon Cytokine Res; 2016 Sep; 36(9):542-51. PubMed ID: 27336613
[TBL] [Abstract][Full Text] [Related]
7. Functional analysis of interferon-alpha subtypes using monoclonal antibodies to interferon-alpha 4a--subtype reactivity, neutralisation of biological activities and epitope analysis.
Overall ML; Hertzog PJ
Mol Immunol; 1992 Mar; 29(3):391-9. PubMed ID: 1372957
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a domain of a human type I interferon receptor protein involved in ligand binding.
Eid P; Tovey MG
J Interferon Cytokine Res; 1995 Mar; 15(3):205-11. PubMed ID: 7584665
[TBL] [Abstract][Full Text] [Related]
9. N-glycosylation of murine IFN-beta in a putative receptor-binding region.
Sommereyns C; Michiels T
J Interferon Cytokine Res; 2006 Jun; 26(6):406-13. PubMed ID: 16734561
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of an interferon-beta1a product.
Kauffman MA; Sterin-Prync A; Papouchado M; González E; Vidal AJ; Grossberg SE; Chuppa S; Odoriz B; Vrech C; Diez RA; Ferro HH
Int J Immunopathol Pharmacol; 2011; 24(2):499-504. PubMed ID: 21658324
[TBL] [Abstract][Full Text] [Related]
11. Activity of hybrid type I interferons in cells lacking Tyk2: a common region of IFN-alpha 8 induces a response, but IFN-alpha2/8 hybrids can behave like IFN-beta.
Platis D; Foster GR
J Interferon Cytokine Res; 2003 Nov; 23(11):655-66. PubMed ID: 14651780
[TBL] [Abstract][Full Text] [Related]
12. Epitope specificity of neutralizing antibodies against IFN-beta.
Gneiss C; Reindl M; Berger T; Lutterotti A; Ehling R; Egg R; Deisenhammer F
J Interferon Cytokine Res; 2004 May; 24(5):283-90. PubMed ID: 15153311
[TBL] [Abstract][Full Text] [Related]
13. Determination of residues involved in ligand binding and signal transmission in the human IFN-alpha receptor 2.
Chuntharapai A; Gibbs V; Lu J; Ow A; Marsters S; Ashkenazi A; De Vos A; Jin Kim K
J Immunol; 1999 Jul; 163(2):766-73. PubMed ID: 10395669
[TBL] [Abstract][Full Text] [Related]
14. Mutational and structural analysis of the binding interface between type I interferons and their receptor Ifnar2.
Piehler J; Schreiber G
J Mol Biol; 1999 Nov; 294(1):223-37. PubMed ID: 10556041
[TBL] [Abstract][Full Text] [Related]
15. Different functional sites on rIFN-alpha 2 and their relation to the cellular receptor binding site.
Cebrián M; Yagüe E; de Landázuri MO; Rodíguez-Moya M; Fresno M; Pezzi N; Llamazares S; Sánchez-Madrid F
J Immunol; 1987 Jan; 138(2):484-90. PubMed ID: 2432126
[TBL] [Abstract][Full Text] [Related]
16. Structure-function study of the extracellular domain of the human type I interferon receptor (IFNAR)-1 subunit.
Kumaran J; Colamonici OR; Fish EN
J Interferon Cytokine Res; 2000 May; 20(5):479-85. PubMed ID: 10841076
[TBL] [Abstract][Full Text] [Related]
17. A peptide mimetic of human interferon (IFN)-beta.
Sato A; Sone S
Biochem J; 2003 Apr; 371(Pt 2):603-8. PubMed ID: 12542398
[TBL] [Abstract][Full Text] [Related]
18. Humanization and epitope mapping of neutralizing anti-human Fas ligand monoclonal antibodies: structural insights into Fas/Fas ligand interaction.
Nisihara T; Ushio Y; Higuchi H; Kayagaki N; Yamaguchi N; Soejima K; Matsuo S; Maeda H; Eda Y; Okumura K; Yagita H
J Immunol; 2001 Sep; 167(6):3266-75. PubMed ID: 11544314
[TBL] [Abstract][Full Text] [Related]
19. Structural analysis of the adenovirus type 2 E3/19K protein using mutagenesis and a panel of conformation-sensitive monoclonal antibodies.
Menz B; Sester M; Koebernick K; Schmid R; Burgert HG
Mol Immunol; 2008 Nov; 46(1):16-26. PubMed ID: 18692902
[TBL] [Abstract][Full Text] [Related]
20. Functional epitopes on porcine endogenous retrovirus envelope protein interacting with neutralizing antibody combining sites.
Chiang CY; Pan YR; Chou LF; Fang CY; Wang SR; Yang CY; Chang HY
Virology; 2007 May; 361(2):364-71. PubMed ID: 17222436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
